P56 SURVIVAL BENEFIT OF BIRTAMIMAB IN MAYO STAGE IV AL AMYLOIDOSIS IN THE PHASE 3 VITAL STUDY WAS CONSISTENT ACROSS ALL KEY BASELINE VARIABLES

oleh: M. Gertz, A. Cohen, R. Comenzo, E. Kastritis, H. Landau, E. Libby, M. Liedtke, V. Sanchorawala, S. Schönland, A. Wechalekar, Y. Ando, Y. Koh, J. Zonder, G. Palladini, C. Nie, C. Karp, Y. Jin, A. Conrad, G. Kinney, G. Merlini